April 1, 2026: Patient Form Temporary Outage Notice – Patient forms will be unavailable tonight from 9:00 PM – 5:00 AM EST due to scheduled maintenance. Access will be restored on April 2, 2026, by 6:00 AM EST. Thank you for your patience.
A liposomal formulation of the prodrug oxaliplatin, an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a ‘leaving group’, with antineoplastic activity. After displacement of the labile oxalate ligand leaving group, the active oxaliplatin derivatives monoaquo and diaquo DACH platinum alkylate macromolecules, and form both inter- and intra-strand platinum-DNA crosslinks; inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity ensue. The DACH side chain appears to inhibit alkylating-agent resistance. A leaving group is an atom or a group of atoms that is displaced as a stable species taking with it its bonding electrons. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
